KRAS Allelic Imbalance Strengths and Weaknesses in Numbers

Gary J Doherty; Emma M Kerr; Carla P Martins

doi:10.1016/j.molmed.2017.03.005

KRAS Allelic Imbalance Strengths and Weaknesses in Numbers

Gary J Doherty, Emma M Kerr, Carla P Martins

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

381 Downloads (Pure)

Abstract

The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

Original language	English
Pages (from-to)	377-378
Journal	Trends in molecular medicine
Volume	23
Issue number	5
DOIs	https://doi.org/10.1016/j.molmed.2017.03.005
Publication status	Published - 31 Mar 2017
Externally published	Yes

Keywords

Allelic Imbalance/genetics
Benzamides/pharmacology
Diphenylamine/analogs & derivatives
Gene Dosage/genetics
Humans
Leukemia/genetics
MAP Kinase Kinase 1/antagonists & inhibitors
MAP Kinase Kinase 2/antagonists & inhibitors
Models, Theoretical
Proto-Oncogene Proteins p21(ras)/genetics

Access to Document

10.1016/j.molmed.2017.03.005Licence: Unspecified

KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers
Copyright 2017 Elsevier. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 372 KBLicence: CC BY-NC-ND

Cite this

@article{fa2dcfb8b42846fba199605ae377c585,

title = "KRAS Allelic Imbalance Strengths and Weaknesses in Numbers",

abstract = "The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.",

keywords = "Allelic Imbalance/genetics, Benzamides/pharmacology, Diphenylamine/analogs & derivatives, Gene Dosage/genetics, Humans, Leukemia/genetics, MAP Kinase Kinase 1/antagonists & inhibitors, MAP Kinase Kinase 2/antagonists & inhibitors, Models, Theoretical, Proto-Oncogene Proteins p21(ras)/genetics",

author = "Doherty, {Gary J} and Kerr, {Emma M} and Martins, {Carla P}",

year = "2017",

month = mar,

day = "31",

doi = "10.1016/j.molmed.2017.03.005",

language = "English",

volume = "23",

pages = "377--378",

journal = "Trends in molecular medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - KRAS Allelic Imbalance Strengths and Weaknesses in Numbers

AU - Doherty, Gary J

AU - Kerr, Emma M

AU - Martins, Carla P

PY - 2017/3/31

Y1 - 2017/3/31

N2 - The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

AB - The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

KW - Allelic Imbalance/genetics

KW - Benzamides/pharmacology

KW - Diphenylamine/analogs & derivatives

KW - Gene Dosage/genetics

KW - Humans

KW - Leukemia/genetics

KW - MAP Kinase Kinase 1/antagonists & inhibitors

KW - MAP Kinase Kinase 2/antagonists & inhibitors

KW - Models, Theoretical

KW - Proto-Oncogene Proteins p21(ras)/genetics

U2 - 10.1016/j.molmed.2017.03.005

DO - 10.1016/j.molmed.2017.03.005

M3 - Article

C2 - 28372922

SN - 1471-4914

VL - 23

SP - 377

EP - 378

JO - Trends in molecular medicine

JF - Trends in molecular medicine

IS - 5

ER -

KRAS Allelic Imbalance Strengths and Weaknesses in Numbers

Abstract

Keywords

Access to Document

Fingerprint

Cite this